financetom
Business
financetom
/
Business
/
Solaris ends plan to sell stake to China's Zijin Mining, cites government rules
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Solaris ends plan to sell stake to China's Zijin Mining, cites government rules
May 21, 2024 9:33 AM

TORONTO, May 21 (Reuters) - Solaris Resources ( SLSR )

has scrapped plans to sell a minority stake to China's Zijin

Mining Group because it feared the deal was unlikely

to meet Canada's stringent foreign- investment standards in a

timely manner, the Canadian company said on Tuesday.

In January, Solaris announced plans to sell a 15% stake in

the company to state-owned Zijin for C$130 million ($95

million)to help develop its Warintza copper project in Ecuador.

But the deal needed approval under the Investment Canada Act,

which was revamped in late 2022 to bring additional scrutiny on

foreign investments from state-owned enterprises in the critical

minerals sector.

"That this transaction cannot be completed in a reasonable

time frame signals that Canada's critical minerals policy is

counterproductive in relation to foreign assets," said Solaris

Resources' ( SLSR ) CEO, Daniel Earle, in a statement.

The company's share price had underperformed compared with

its peers due to the overhang of Canadian regulatory uncertainty

"in an environment of heightened domestic political

sensitivity," Earle added.

The stock was down 0.4% on the Toronto Stock Exchange late

on Tuesday morning, compared with 0.3% rise in the benchmark

Canadian share index.

In a research note, RBC Capital Markets said the scrapping

of the deal removes regulatory uncertainty and the dilutive

value of the transaction.

Canada's government has taken a tough stance specifically on

investments from China in critical minerals such as copper,

graphite and lithium. Earlier this year, Canada asked SRG Mining ( SRGMF )

, a graphite miner, to call off a planned investment from

China's Carbon One New Energy Group.

($1 = 1.3641 Canadian dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vertiv Hldgs Unusual Options Activity For June 18
Vertiv Hldgs Unusual Options Activity For June 18
Jun 18, 2024
Whales with a lot of money to spend have taken a noticeably bullish stance on Vertiv Hldgs ( VRT ). Looking at options history for Vertiv Hldgs ( VRT ) we detected 17 trades. If we consider the specifics of each trade, it is accurate to state that 47% of the investors opened trades with bullish expectations and 41% with...
Neurogene Doses First Patient in High-Dose Group of Rett Syndrome Trial
Neurogene Doses First Patient in High-Dose Group of Rett Syndrome Trial
Jun 18, 2024
10:43 AM EDT, 06/18/2024 (MT Newswires) -- Neurogene ( NGNE ) said Tuesday that the first patient in cohort 2 received high-dose NGN-401 gene therapy in a phase 1/2 trial for female pediatric patients with the neurodevelopmental disorder Rett syndrome. The company said that high-dose NGN-401 has been well-tolerated following dosing in May. NGN-401 is an investigational adeno-associated virus, or...
TC Energy Ratings Affirmed by S&P
TC Energy Ratings Affirmed by S&P
Jun 18, 2024
10:42 AM EDT, 06/18/2024 (MT Newswires) -- S&P Global Ratings on Monday affirmed its BBB+ issuer credit rating on TC Energy ( TRP ) and all issue-level ratings on the company's outstanding debt. The negative outlook reflects our belief that while TC has made progress on deleveraging, there still is some uncertainty that might prevent the company from achieving a...
Ionis Pharmaceuticals Says Otsuka Obtains Rights for Investigational Hereditary Angioedema Treatment in Asia Pacific
Ionis Pharmaceuticals Says Otsuka Obtains Rights for Investigational Hereditary Angioedema Treatment in Asia Pacific
Jun 18, 2024
10:43 AM EDT, 06/18/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Tuesday it signed a license agreement with Otsuka Pharmaceutical giving Otsuka exclusive rights for donidalorsen, an investigational treatment for hereditary angioedema, across the Asia-Pacific region. Ionis said it will receive a $20 million upfront payment and milestone payments based on the achievement of regulatory and sales targets,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved